Date: 2016-07-07
Type of information: R&D agreement
Compound: Beleodaq® derivatives
Company: Onxeo (France) Royal College of Surgeons in Ireland (RCSI) (Ireland)
Therapeutic area: Cancer - Oncology
Type agreement: R&D collaboration
Action mechanism: histone deacetylase inhibitor. Belinostat is a small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid tumors and hematologic malignancies either as a single agent, or in combination with other active anti-cancer agents, including carboplatin, paclitaxel, doxorubicin, idarubicin, cis-retinoic acid, azacytidine, 5-FU, etoposide and bortezomib for injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to: Arrest growth of cancer cells (including drug-resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents. Beleodaq® (belinostat) has received accelerated approval by the FDA for the treatment of relapsed or refractory peripheral T-cell lymphoma in July 2014.
Disease:
Details: * On July 7, 2016, Onxeo announced a collaboration with the Royal College of Surgeons in Ireland (RCSI) for a discovery-stageprogram on the derivatives of belinostat (Beleodaq®), a histone deacetylase (HDAC) inhibitor.
This new collaboration program aims at optimizing the pharmacokinetic profile of belinostat, in order to increase its lifetime, its efficacy and its stability. In the end, the goal is to develop conjugate molecules derived from belinostat and with distinctive features compared to existing HDAC inhibitors, which may lead to new patent opportunities. The research projects will be led by Pr. Celine Marmion, Associate Professor of Bioinorganic Chemistry at RCSI and specialized in rational drug design, synthesis and pharmacological evaluation of metal-based anti-cancer agents.
According to the terms of the agreement, research costs will be shared between Onxeo and RCSI. Onxeo will have an option to license RCSI’s patents at negotiated rates. RCSI will lead compounds synthesis and in vitro testing, and Onxeo will lead the in vivo studies.
Financial terms:
Latest news:
